FAS Wealth Partners Inc. Buys 51,460 Shares of ARS Pharmaceuticals, Inc. $SPRY

FAS Wealth Partners Inc. increased its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 34.5% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 200,620 shares of the company’s stock after purchasing an additional 51,460 shares during the quarter. FAS Wealth Partners Inc. owned about 0.20% of ARS Pharmaceuticals worth $2,016,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the stock. CWM LLC grew its holdings in ARS Pharmaceuticals by 243.7% during the 3rd quarter. CWM LLC now owns 2,547 shares of the company’s stock valued at $26,000 after buying an additional 1,806 shares in the last quarter. Osaic Holdings Inc. boosted its position in shares of ARS Pharmaceuticals by 52.8% in the second quarter. Osaic Holdings Inc. now owns 5,215 shares of the company’s stock valued at $91,000 after acquiring an additional 1,803 shares during the period. CX Institutional bought a new position in shares of ARS Pharmaceuticals in the third quarter valued at approximately $92,000. Ameritas Investment Partners Inc. grew its stake in ARS Pharmaceuticals by 16.1% during the second quarter. Ameritas Investment Partners Inc. now owns 5,598 shares of the company’s stock valued at $98,000 after acquiring an additional 777 shares in the last quarter. Finally, RiverPark Advisors LLC bought a new stake in ARS Pharmaceuticals during the 2nd quarter worth approximately $100,000. Hedge funds and other institutional investors own 68.16% of the company’s stock.

ARS Pharmaceuticals Stock Performance

NASDAQ SPRY opened at $10.63 on Friday. ARS Pharmaceuticals, Inc. has a 52-week low of $6.66 and a 52-week high of $18.90. The company has a fifty day moving average of $10.09 and a 200-day moving average of $11.96. The company has a market capitalization of $1.05 billion, a P/E ratio of -13.12 and a beta of 0.80. The company has a debt-to-equity ratio of 1.14, a quick ratio of 6.51 and a current ratio of 6.66.

ARS Pharmaceuticals (NASDAQ:SPRY) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.07). ARS Pharmaceuticals had a negative net margin of 56.06% and a negative return on equity of 38.77%. The firm had revenue of $32.50 million for the quarter, compared to analysts’ expectations of $28.87 million. As a group, equities research analysts predict that ARS Pharmaceuticals, Inc. will post -0.55 EPS for the current fiscal year.

Insider Buying and Selling

In other ARS Pharmaceuticals news, insider Justin Chakma sold 166,380 shares of ARS Pharmaceuticals stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $8.87, for a total transaction of $1,475,790.60. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Brian Dorsey sold 21,828 shares of the company’s stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $8.71, for a total transaction of $190,121.88. Following the completion of the sale, the chief operating officer directly owned 10,789 shares of the company’s stock, valued at $93,972.19. This trade represents a 66.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 33.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on SPRY shares. Zacks Research raised shares of ARS Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Thursday, November 20th. Raymond James Financial set a $32.00 price objective on ARS Pharmaceuticals in a research report on Friday, September 26th. Roth Capital began coverage on ARS Pharmaceuticals in a research report on Tuesday, November 4th. They set a “buy” rating and a $30.00 target price for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of ARS Pharmaceuticals in a research note on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, ARS Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $33.00.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.